Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Acquisitions & Divestments: 2020-2024

Historic Change in Acquisitions & Divestments for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $40.2 million.

  • Xeris Biopharma Holdings' Change in Acquisitions & Divestments fell 31.76% to $10.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $40.2 million, marking a year-over-year decrease of 18.39%. This contributed to the annual value of $40.2 million for FY2024, which is 0.59% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Change in Acquisitions & Divestments of $40.2 million as of FY2024, which was up 0.59% from $40.0 million recorded in FY2023.
  • Xeris Biopharma Holdings' 5-year Change in Acquisitions & Divestments high stood at $103.6 million for FY2021, and its period low was $35.0 million during FY2022.
  • Its 3-year average for Change in Acquisitions & Divestments is $38.4 million, with a median of $40.0 million in 2023.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Change in Acquisitions & Divestments spiked by 38.60% in 2021, and later plummeted by 66.23% in 2022.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' Change in Acquisitions & Divestments stood at $74.7 million in 2020, then soared by 38.60% to $103.6 million in 2021, then slumped by 66.23% to $35.0 million in 2022, then rose by 14.33% to $40.0 million in 2023, then rose by 0.59% to $40.2 million in 2024.